Long-acting drug delivery systems : (Record no. 82627)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 12012cam a2200637 a 4500 |
| 001 - CONTROL NUMBER | |
| control field | on1269054953 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20230516165951.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr |n||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 210924s2022 enk o 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | YDX |
| Language of cataloging | eng |
| Description conventions | pn |
| Transcribing agency | YDX |
| Modifying agency | OPELS |
| -- | OCLCF |
| -- | OCLCO |
| -- | OCLCQ |
| -- | OCLCO |
| -- | K6U |
| -- | SFB |
| -- | OCLCQ |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780128217597 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 0128217596 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9780128217498 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 0128217499 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1269054953 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RS199.5 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.6 |
| Edition number | 23 |
| 245 00 - TITLE STATEMENT | |
| Title | Long-acting drug delivery systems : |
| Remainder of title | pharmaceutical, clinical, and regulatory aspects / |
| Statement of responsibility, etc. | edited by Eneko Larraneta, Thakur Raghu Raj Singh, Ryan F. Donnelly. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Duxford : |
| Name of publisher, distributor, etc. | Woodhead Publishing, |
| Date of publication, distribution, etc. | 2022. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Woodhead Publishing Series in Biomaterials |
| 588 0# - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Print version record. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Front Cover -- Long-Acting Drug Delivery Systems -- Copyright Page -- Contents -- List of contributors -- Preface -- 1 Overview of the clinical current needs and potential applications for long-acting and implantable delivery systems -- 1.1 Introduction -- 1.2 LADDS versus conventional routes for drug administration -- 1.3 Current applications of long-acting drug delivery system -- 1.3.1 Contraception -- 1.3.2 Cancer -- 1.3.3 Ocular diseases -- 1.3.4 Chronic conditions and other applications -- 1.4 Future applications of long-acting drug delivery system -- References -- 2 Classification, material types, and design approaches of long-acting and implantable drug delivery systems -- 2.1 Introduction -- 2.2 Implantable polymeric drug delivery device classification -- 2.2.1 Solid implants -- 2.2.1.1 Passive implants -- 2.2.1.2 Active implants -- 2.2.2 Injectable long-acting formulations -- 2.2.2.1 Long-acting nano/microparticle suspensions -- 2.2.2.2 In situ forming implants -- Phase separation systems -- Hydrogels -- Organogels -- 2.3 Mechanism of drug release from implantable and long-acting drug delivery systems -- 2.3.1 Mechanism of drug release from solid implants -- 2.3.2 Mechanism of release from nano/microparticulate injectable formulations -- 2.3.3 Mechanism of release from in situ forming implants -- 2.4 Materials used for implantable and long-acting drug delivery systems manufacturing -- 2.4.1 Materials used for solid implant manufacturing -- 2.4.1.1 Polymeric materials -- Biodegradable polymers -- Aliphatic polyesters -- Poly(lactic acid) -- Poly(glycolic acid) -- Poly(lactic-co-glycolic acid) -- Poly(caprolactone) -- Other biodegradable polymers -- Non biodegradable polymers -- Poly(siloxanes) -- Poly(ethylene-vinyl acetate) -- Polyurethanes -- 2.4.1.2 Natural polymers -- Cellulose -- Chitosan -- Silk -- 2.4.1.3 Nonpolymeric materials. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Metals -- Hydroxyapatite and tricalcium phosphate -- Other nonpolymeric materials -- 2.4.2 Materials used to prepare injectable long-acting formulations -- 2.4.2.1 Long-acting nano/microparticle suspensions -- 2.4.2.2 In situ forming implants -- Hydrogels -- Hyaluronic acid -- Alginate -- Collagen and gelatin -- Block copolymers -- Poly(N-isopropylacrylamide) -- Organogels -- 2.5 Manufacturing methods of implants and long-acting formulations -- 2.5.1 Manufacturing of solid implants -- 2.5.1.1 Compression -- 2.5.1.2 Solvent casting -- 2.5.1.3 Hot melt extrusion -- 2.5.1.4 Injection molding -- 2.5.1.5 Electrospinning -- 2.5.1.6 3D printing -- 2.5.2 Methods to prepare in situ forming injectable implants -- 2.5.2.1 Methods of micro/nanosuspension and micro/nanoparticle preparation -- Spray drying -- Microfluidics -- Electrospraying -- Milling -- High pressure homogenization and ultrasonication -- 2.6 Implantable polymeric device design -- 2.7 Conclusions -- References -- 3 Long-acting drug delivery systems for ocular therapies -- 3.1 Introduction -- 3.2 Contact lenses and other ocular inserts on the surface as long-acting systems -- 3.3 Long-acting systems for the anterior segment -- 3.4 Periocular delivery of long-acting systems -- 3.5 Long-acting intravitreal systems -- 3.6 Long-acting micro/nanoparticulate delivery systems -- 3.7 In situ forming long-acting implants for ocular delivery -- 3.8 Conclusion and future directions -- References -- 4 Applications of long-lasting and implantable drug delivery systems for cardiovascular disease treatment -- 4.1 Introduction: Cardiovascular disease and atherosclerosis -- 4.2 Pathophysiology of atherosclerosis -- 4.3 Treatments for atherosclerosis -- 4.4 Stenting -- 4.5 Future directions in stent development -- 4.6 3D printing -- 4.7 Stents manufactured via selective laser sintering. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 4.8 Stents manufactured via MJ -- 4.9 Stents manufactured via stereolithography -- 4.10 Two-photon polymerization -- 4.11 Targeted treatments for other CVDs -- 4.12 Conclusion -- References -- 5 Implantable and long-lasting drug delivery systems for cancer treatment -- 5.1 Introduction -- 5.2 Implantable drug delivery systems -- 5.2.1 Nonbiodegradable versus biodegradable implantable drug delivery systems -- 5.2.2 Implantable drug delivery systems applications in cancer treatment -- 5.2.2.1 Chemotherapy -- 5.2.2.2 Induce hyperthermia -- 5.2.2.3 Photodynamic therapy -- 5.2.2.4 Gene therapy -- 5.2.2.5 Immunotherapy -- 5.3 Conclusion -- Acknowledgments -- References -- 6 Long-acting drug delivery systems: applications for sexual and reproductive health -- 6.1 Introduction -- 6.2 Sexual and reproductive health physical and pathological challenges -- 6.3 Different approaches to conquer the physical and pathological obstacles associated with sexual and reproductive health -- 6.4 Drug delivery systems used in the field of sexual and reproductive health -- 6.4.1 Nanomedicine and nanoparticles -- 6.4.1.1 Reproductive cancers -- 6.4.1.2 Endometriosis -- 6.4.1.3 Uterine fibroids -- 6.4.1.4 Pregnancy -- 6.4.1.5 HIV and genital infections -- 6.4.1.6 Assisted reproductive technology -- 6.4.1.7 Erectile dysfunction -- 6.4.2 Exosomes -- 6.4.2.1 Breast cancer -- 6.4.2.2 Obstetrical applications of exosomes -- 6.4.3 Liposomes -- 6.4.3.1 Breast cancer -- 6.4.3.2 Ovarian cancer -- 6.4.3.3 Treatment of HIV complications -- 6.4.3.4 Preterm labor -- 6.4.3.5 Prostate cancer -- 6.4.3.6 Erectile dysfunction -- 6.4.4 Micelles -- 6.4.5 Liquid crystals -- 6.4.6 Polymer gels -- 6.4.7 Sperm-hybrid micromotors for drug delivery in the female reproductive tract -- 6.5 Advances in long-acting contraceptive drug delivery systems -- 6.5.1 Copper-bearing intrauterine devices. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 6.5.2 Levonorgestrel-releasing intrauterine system -- 6.5.3 Progestin-containing subdermal contraceptive implants -- 6.5.4 Effervescent microneedle patch -- 6.6 Advances in long-acting drug delivery systems in AIDS prophylaxis -- 6.7 Conclusion -- Acknowledgments -- References -- 7 Long-acting drug delivery systems for schizophrenia treatment -- 7.1 Introduction -- 7.1.1 LAI formulations -- 7.2 Who would benefit from LAI antipsychotics: understanding the indications through mechanism -- 7.2.1 Adherence translates into effectiveness -- 7.2.2 Direct medical supervision enhances the outcome -- 7.2.3 Pharmacokinetics of LAI antipsychotics influencing the clinical decisions -- 7.2.4 Pharmacodynamics: differences in dopamine receptor antagonism -- 7.2.5 LAI antipsychotic may reverse altered receptor sensitivity -- 7.2.6 Neuroplasticity -- 7.3 Special indications -- 7.4 Evidence for superiority of LAI antipsychotic over oral antipsychotics -- 7.5 When to start LAI? -- 7.6 Comparative tolerability of LAI antipsychotics -- 7.7 How to initiate LAI antipsychotic? -- 7.8 Choosing among FGA LAIs and SGA LAIs: newer the better or old is gold? -- 7.9 Clinical utility of LAI antipsychotics: the ground reality -- 7.10 Noninjectable long-acting formulations -- 7.11 Conclusion -- Acknowledgment -- Conflict of interest -- References -- 8 Implantable and long-lasting drug delivery systems for infectious, inflammatory, endocrine, and neurodegenerative diseases -- 8.1 Introduction -- 8.2 Implantable and long-lasting drug delivery systems for infectious diseases -- 8.2.1 Tuberculosis -- 8.2.2 Malaria -- 8.2.3 Hepatitis B -- 8.3 Implantable and long-lasting drug delivery systems for inflammatory diseases -- 8.3.1 Osteoarthritis -- 8.3.2 Long-acting delivery of NSAID drugs -- 8.3.3 Long-acting delivery of steroid drugs. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 8.4 Implantable and long-lasting drug delivery systems for endocrine diseases -- 8.4.1 Hypothyroidism -- 8.4.2 Growth hormone -- 8.5 Implantable and long-lasting drug delivery systems for neurodegenerative diseases -- References -- 9 Long-lasting drug delivery systems based on microneedles -- 9.1 Introduction -- 9.2 Microneedle array patch as a long-acting drug delivery tool -- 9.2.1 Type of microneedle array patch formulations -- 9.3 Long-acting microneedle array patch formulations -- 9.3.1 Microneedle array patches formulation methodologies for long-acting delivery -- 9.3.1.1 Nano/microparticles delivery by microneedle array patch -- 9.3.1.2 Slow dissolving microneedle array patch -- Poly(lactide-co-glycolide)/polylactic acid microneedle array patches -- Silk fibroin microneedle array patches -- Chitosan microneedle array patches -- 9.3.1.3 Stimuli-responsive smart microneedle array patch -- 9.3.1.4 Hollow microneedles -- 9.4 Application of microneedle array patches for long-acting drug delivery -- 9.4.1 Vaccine -- 9.4.2 Lymphatic targeting -- 9.4.3 HIV infection -- 9.4.4 Contraceptives -- 9.4.5 Antipsychotics -- 9.4.6 Insulin -- 9.4.7 Skin diseases -- 9.5 Laboratory to large-scale considerations -- 9.6 Conclusion and future prospects of microneedle array patch -- References -- 10 Safety, biodegradability, and biocompatibility considerations of long-acting drug delivery systems -- 10.1 Introduction -- 10.2 Biodegradation as per international regulatory bodies -- 10.2.1 Experimental design consideration for the fabrication of biodegradable implants -- 10.2.2 Initial quantification of implants before degradation studies -- 10.2.3 Preparation of biodegradation medium -- 10.2.4 Containers -- 10.2.5 Number of samples -- 10.2.6 Experimental procedure -- 10.2.7 Real-time biodegradation -- 10.2.8 Accelerated degradation -- 10.2.9 Final characterization. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug delivery systems. |
| 9 (RLIN) | 7290 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug delivery systems |
| General subdivision | Technological innovations. |
| 9 (RLIN) | 69297 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drugs |
| General subdivision | Controlled release. |
| 9 (RLIN) | 69525 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biomedical materials. |
| 9 (RLIN) | 3868 |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Delivery Systems |
| Authority record control number or standard number | (DNLM)D016503 |
| 9 (RLIN) | 7290 |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Delayed-Action Preparations |
| Authority record control number or standard number | (DNLM)D003692 |
| 9 (RLIN) | 69526 |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biocompatible Materials |
| Authority record control number or standard number | (DNLM)D001672 |
| 9 (RLIN) | 5921 |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biomedical and Dental Materials |
| Authority record control number or standard number | (DNLM)D001697 |
| 9 (RLIN) | 68432 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Syst�emes d'administration de m�edicaments. |
| Authority record control number or standard number | (CaQQLa)000260397 |
| 9 (RLIN) | 69527 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Syst�emes d'administration de m�edicaments |
| Authority record control number or standard number | (CaQQLa)000260397 |
| General subdivision | Innovations. |
| Authority record control number or standard number | (CaQQLa)201-0379286 |
| 9 (RLIN) | 69298 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | M�edicaments-retard. |
| Authority record control number or standard number | (CaQQLa)201-0059667 |
| 9 (RLIN) | 69528 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biomat�eriaux. |
| Authority record control number or standard number | (CaQQLa)201-0025723 |
| 9 (RLIN) | 68433 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biomedical materials. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst00832586 |
| 9 (RLIN) | 3868 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug delivery systems. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst00898667 |
| 9 (RLIN) | 7290 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drugs |
| General subdivision | Controlled release. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst00898783 |
| 9 (RLIN) | 69525 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Larraneta, Eneko. |
| 9 (RLIN) | 69529 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Singh, Thakur Raghu Raj. |
| 9 (RLIN) | 69530 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Donnelly, Ryan F. |
| 9 (RLIN) | 69531 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Title | Long-acting drug delivery systems. |
| Place, publisher, and date of publication | Duxford : Woodhead Publishing, 2022 |
| International Standard Book Number | 0128217499 |
| -- | 9780128217498 |
| Record control number | (OCoLC)1226566666 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Title | Long-acting drug delivery systems |
| International Standard Book Number | 9780128217498 |
| Record control number | (OCoLC)1259524364 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Woodhead Publishing series in biomaterials. |
| 9 (RLIN) | 68481 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Materials specified | ScienceDirect |
| Uniform Resource Identifier | <a href="https://www.sciencedirect.com/science/book/9780128217498">https://www.sciencedirect.com/science/book/9780128217498</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | eBooks |
No items available.